Wollastonite
Based on 1 Customer Validation
Wollastonite is a white, chain-structured pyroxene silicate mineral with biocompatibility, biodegradability, osteogenicity and antibacterial properties. Wollastonite induces transient pulmonary inflammatory responses, reversible alveolar macrophage responses, early inflammatory/proliferative mesothelial cell responses, ROS production, and mild chronic pulmonary interstitial inflammation in rats. Wollastonite induces osteogenic differentiation, promotes bone growth, supports angiogenesis, and facilitates the formation of hydroxycarbonate apatite on its surface. Wollastonite enhances the strength, bioactivity and biodegradability of hydroxyapatite scaffolds, and is used to construct porous bone tissue engineering scaffolds. Wollastonite is applied in research related to diseases such as bronchitis, decreased lung function and bone defects.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 13983-17-0
- Formule: CaH2O3Si
- Masse moléculaire:118.18
-
Stockage:
Store at room temperature, keep dry and cool.
In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Wollastonite exhibits higher strength than traditional porcelain in low-temperature fired ceramics (67 MPa at 1200°C), along with the characteristics of lower firing temperature, less energy consumption and self-glazing; it shows better glossiness, spreadability and whiteness in glaze formulations; in facing tile mixtures, it reduces drying/firing shrinkage and wet expansion rate, and improves deformation resistance, heat resistance and frost resistance[1].
Wollastonite exhibits significantly lower cytotoxicity towards cultured rabbit alveolar macrophages than chrysotile asbestos; it also has lower hemolytic potential and induces lower levels of lipid peroxidation in red blood cells; in cell-free deoxyribose and PMN leukocyte systems, it generates higher levels of non-hydroxyl radical reactive oxygen species than asbestos[2].
Wollastonite (10 wt%) increases the water absorption rate of PHBV scaffolds by 44.1% compared with pure PHBV scaffolds, thereby enhancing their applicability in biological applications[3].
Wollastonite coatings can form hydroxycarbonate apatite upon immersion in simulated body fluid, exhibiting in vitro bioactivity[3].
Wollastonite glass-ceramic scaffolds support the growth and adhesion of human mesenchymal stem cells, and form a fused cell layer after 21 days of osteogenic culture[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Wollastonite (10 mg/m3; administered via inhalation; 6 hours per day, 5 days per week; for 12 or 24 months) induces mild interstitial fibrosis in male F344 rats, but does not increase their pulmonary tumor incidence[2].
Wollastonite (50-100 mg/m3; inhalation exposure; 6 hours per day; for 3 or 5 consecutive days) induces transient and milder pulmonary inflammatory responses in male Crl:CDBR rats compared with Crocidolite[2].
Wollastonite (25 mg; intratracheal administration; single dose) induces mild to moderate pulmonary effects in male Wistar rats[2].
Wollastonite (1 mg; intratracheal administration; single dose) induces mild, non-progressive chronic interstitial inflammation in male Sprague-Dawley rats within 6 months[2].
Wollastonite (114 mg/m3; exposed via inhalation; 6 hours per day for 5 consecutive days) has a retention half-life of less than 1 week in male Crl:CDBR rats, indicating that it can be rapidly cleared from the lungs[2].
Wollastonite-based scaffolds doped with dilute magnesium (CSi-Mgx) fabricated via 3D printing (surgical implantation; single administration) exhibit excellent strength, degradability and osteogenic capacity, rendering them promising for bone regeneration of thin-wall bone defects in rabbits[3].
Wollastonite-hydroxyapatite composite biomaterial (surgical implantation; single administration) safely enhances vascularization and promotes new bone formation at the surgical defect site of the femur in rats at 12 weeks post-implantation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Osborne-Mendel (female, 12-20 weeks of age, intrapleural fiber-induced pleural sarcoma model)[2]
-
Dosage:40 mg/animal
-
Administration:intrapleural; single dose
-
Result:Produced variable pleural sarcoma incidence by wollastonite grade: grade 1 (25%, 5/20), grade 2 (8%, 2/25), grade 3 (14.3%, 3/21), grade 4 (0%, 0/24).
-
Animal Model:Crl:CDBR (male, short-term inhalation exposure model)[2]
-
Dosage:50, 100 mg/m3
-
Administration:inhalation; 6 hours/day; 3 or 5 days
-
Result:Produced transient pulmonary inflammatory responses and increases in BAL fluid parameters only when the mass median aerodynamic diameter (MMAD) was 2.6 μm and exposure concentration exceeded 500 fibers/mL; the severity and duration of responses were less than those induced by crocidolite.
-
Animal Model:Crl:CDBR (male, 8 weeks of age, inhalation exposure model)[2]
-
Dosage:114 mg/m3
-
Administration:inhalation; 6 hours/day; 5 days
-
Result:Cleared rapidly from the lungs, with a retention half-time of <1 week.
Chemical Information
-
CAS No. 13983-17-0
-
Appearance Solid
-
Masse moléculaire 118.18
-
Formule CaH2O3Si
-
SMILES
[Ca][Si](O[O])=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Store at room temperature, keep dry and cool
In solvent -80°C 1 year -20°C 6 months
Pureté et documentation
Références
[2]. Maxim LD, et al. A review of the toxicology and epidemiology of wollastonite. Inhalation toxicology. 2005 Aug;17(9):451-66. [Content Brief]
[3]. Zenebe CG, et al. A Review on the Role of Wollastonite Biomaterial in Bone Tissue Engineering. BioMed research international. 2022;2022:4996530. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Wollastonite Related Classifications
HY-W584165 Related Classifications
Powered by Bioz
- Wollastonite
- 13983-17-0
- Biochemical Assay Reagents
- Drug Intermediate
- Reactive Oxygen Species (ROS)
- mesothelial cell
- poly(3-hydroxybutyrate-co-3-hydroxy valerate)
- hydroxycarbonate apatite
- PMN leukocyte
- alveolar macrophage
- rabbit alveolar macrophages
- red blood cells
- hydroxyapatite
- reactive oxygen species
- human mesenchymal stem cells
- Inhibitor
- inhibitor
- inhibit